The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Plaque psoriasis is the most common type of psoriasis and the one that often appears on the scalp. It causes raised ... making them easier to remove. Coal tar products are available OTC as ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Plaque psoriasis is characterized by raised ... Scalp psoriasis shows up as itchy, scaly patches on the scalp that may bleed if you try to remove them. About half of people who have psoriasis ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...

The favorable data provided support for two ongoing phase III, randomized, placebo-controlled trials of ESK-001 in moderate/severe plaque psoriasis ... Examples include scalp, hands and feet ...